IDE-397 is a small molecule commercialized by Ideaya Biosciences, with a leading Phase II program in Transitional Cell Cancer (Urothelial Cell Cancer). According to Globaldata, it is involved in 3 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of IDE-397s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for IDE-397 is expected to reach an annual total of $81 mn by 2036 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
IDE-397 Overview
IDE397 is under development for the treatment of solid tumor, non-small cell lung cancer, pancreatic cancer, squamous non-small cell lung cancer ,adenoid cystic carcinoma (ACC), thymic cancer, colorectal cancer, esophagogastric, bladder and urothelial cell cancer. They act by targeting MAT2A (methionine adenosyltransferase 2A) in tumor cells having MTAP gene deletion. The drug candidates are developed based on synthetic lethality drug discovery platform. It is administered through oral route.
The drug candidate was also under the development of head and neck cancer.
Ideaya Biosciences Overview
Ideaya Biosciences (Ideaya) is a precision medicine company that develops oncology therapeutics. The companys product pipeline includes darovasertib (IDE196), a protein kinase C (PKC) inhibitor that targets cancers with GNAQ and GNA11 mutations. Ideaya develops small molecule inhibitors based on synthetic lethality against known and novel targets. It also provides solutions for treating tumors with genetic mutations in homologous recombination deficiency(HRD) and high microsatellite instability (MSI). Ideaya is headquartered in South San Francisco, California, the US.
The company reported revenues of (US Dollars) US$23.4 million for the fiscal year ended December 2023 (FY2023), a decrease of 54.1% over FY2022. The operating loss of the company was US$134.4 million in FY2023, compared to an operating loss of US$62.5 million in FY2022. The net loss of the company was US$113 million in FY2023, compared to a net loss of US$58.7 million in FY2022.
For a complete picture of IDE-397s valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.